Safety and Effectiveness of Recombinant Human Growth Hormone in Children with Turner Syndrome: Data from the PATRO Children Study.

Abstract

INTRODUCTION:

PATRO Children is an international, observational, postmarketing surveillance study for a biosimilar recombinant human growth hormone (rhGH; somatropin, Omnitrope®; Sandoz), approved by the European Medicines Agency in 2006. We report safety and effectiveness data for patients with Turner syndrome (TS).

METHODS:

The study population included infants, children, and adolescents with TS who received Omnitrope® treatment according to standard clinical practice. Adverse events (AEs) were monitored for safety evaluation, and height velocity (HV), height standard deviation score (HSDS), and HVSDS were calculated to evaluate treatment effectiveness.

RESULTS:

As of August 2019, 348 TS patients were enrolled from 130 centers. At baseline, 314 patients (90.2%) were prepubertal and 284 patients (81.6%) were rhGH treatment naïve. The mean (range) age at baseline was 9.0 (0.7-18.5) years, and mean (SD) treatment duration in the study was 38.5 (26.8) months. Overall, 170 patients (48.9%) reported AEs, which were considered treatment related in 25 patients (7.2%). One treatment-related serious AE was reported (intracranial hypertension). Mean ΔHSDS after 3 years of therapy was +1.17 in treatment-naïve prepubertal patients and +0.1 in pretreated prepubertal patients. In total, 51 patients (31.1%) reached adult height (AH), 35 of whom were rhGH treatment naïve; in these patients, mean (SD) HSDS was -2.97 (1.03) at the start of Omnitrope® treatment, and they achieved a mean (SD) AHSDS of -2.02 (0.9).

CONCLUSION:

These data suggest that biosimilar rhGH is well tolerated and effective in TS patients managed in real-life clinical practice. Optimization of rhGH dose may contribute to a higher AH.

• Authors: Philippe Backeljauw, Shankar Kanumakala, Sandro Loche, Karl Otfried Schwab, Roland Werner Pfäffle, Charlotte Höybye, Elena Lundberg, Tadej Battelino, Berit Kriström, Tomasz Giemza, Hichem Zouater
• Journal: Hormone research in paediatrics (Horm Res Paediatr) Vol. 94 Issue 3-4 Pg. 133-143 ( 2021) ISSN: 1663-2826 [Electronic] Switzerland
• PMID: 34350858 (Publication Type: Clinical Trial, Journal Article, Multicenter Study)
• Copyright: The Author(s). Published by S. Karger AG, Basel.

Chemical References

• Human Growth Hormone

Topics

• Child
• Child, Preschool
• Female
• Human Growth Hormone (administration & dosage, adverse effects)
• Humans
• Longitudinal Studies
• Treatment Outcome
• Turner Syndrome (drug therapy, physiopathology)